A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19.
A549 Cells
Angiotensin-Converting Enzyme 2
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Antiviral Agents
/ pharmacology
Betacoronavirus
/ drug effects
COVID-19
Chlorocebus aethiops
Coronavirus Infections
/ diagnosis
High-Throughput Screening Assays
/ methods
Humans
Luciferases
/ genetics
Neutralization Tests
/ methods
Pandemics
Peptidyl-Dipeptidase A
/ metabolism
Pneumonia, Viral
/ diagnosis
SARS-CoV-2
Vero Cells
Virus Internalization
/ drug effects
Virus Replication
/ drug effects
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
15 10 2020
15 10 2020
Historique:
received:
22
06
2020
accepted:
21
09
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
27
10
2020
Statut:
epublish
Résumé
A high-throughput platform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing and antiviral screening. Here we present a high-throughput nanoluciferase severe respiratory syndrome coronavirus 2 (SARS-CoV-2-Nluc) that is genetically stable and replicates similarly to the wild-type virus in cell culture. SARS-CoV-2-Nluc can be used to measure neutralizing antibody activity in patient sera within 5 hours, and it produces results in concordance with a plaque reduction neutralization test (PRNT). Additionally, using SARS-CoV-2-Nluc infection of A549 cells expressing human ACE2 receptor (A549-hACE2), we show that the assay can be used for antiviral screening. Using the optimized SARS-CoV-2-Nluc assay, we evaluate a panel of antivirals and other anti-infective drugs, and we identify nelfinavir, rupintrivir, and cobicistat as the most selective inhibitors of SARS-CoV-2-Nluc (EC
Identifiants
pubmed: 33060595
doi: 10.1038/s41467-020-19055-7
pii: 10.1038/s41467-020-19055-7
pmc: PMC7567097
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antiviral Agents
0
Luciferases
EC 1.13.12.-
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5214Subventions
Organisme : NIAID NIH HHS
ID : R01 AI114657
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI146081
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001440
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : ErratumIn
Références
J Virol. 2007 Apr;81(8):3992-4001
pubmed: 17267485
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6679-6691
pubmed: 27572398
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
J Med Chem. 2014 Mar 13;57(5):2033-46
pubmed: 24320933
Virus Res. 2014 Aug 30;189:262-70
pubmed: 24930446
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5135-40
pubmed: 27216057
Antimicrob Agents Chemother. 2003 Dec;47(12):3907-16
pubmed: 14638501
J Acquir Immune Defic Syndr. 2017 May 1;75(1):61-66
pubmed: 28196003
Antiviral Res. 2020 Jun;178:104786
pubmed: 32251767
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
Curr Protoc Microbiol. 2020 Sep;58(1):e108
pubmed: 32585083
ACS Infect Dis. 2020 May 8;6(5):909-915
pubmed: 32125140
Adv Exp Med Biol. 2006;581:597-600
pubmed: 17037604
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2428-2436
pubmed: 31133531
Bioorg Med Chem Lett. 2012 Feb 1;22(3):1394-6
pubmed: 22244938
PLoS Pathog. 2015 Jun 22;11(6):e1004995
pubmed: 26098424
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Antimicrob Agents Chemother. 1999 Oct;43(10):2444-50
pubmed: 10508022
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Antimicrob Agents Chemother. 2008 Feb;52(2):648-54
pubmed: 18056281
Clin Microbiol Rev. 2003 Oct;16(4):569-96
pubmed: 14557287
J Virol. 2005 Mar;79(6):3846-50
pubmed: 15731278
Bioorg Med Chem Lett. 2016 Jul 15;26(14):3248-3252
pubmed: 27265257
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
Biosci Trends. 2020 Mar 16;14(1):72-73
pubmed: 32074550
Travel Med Infect Dis. 2020 Mar - Apr;34:101663
pubmed: 32289548
J Antimicrob Chemother. 2004 Jan;53(1):4-9
pubmed: 14657084
Antivir Chem Chemother. 2011 Aug 23;22(1):23-49
pubmed: 21860070
Antivir Chem Chemother. 2003 Sep;14(5):235-41
pubmed: 14694986
ACS Med Chem Lett. 2010 May 17;1(5):209-13
pubmed: 24900196
Hepatology. 2012 Feb;55(2):419-28
pubmed: 22006541
Curr Hematol Malig Rep. 2019 Jun;14(3):197-205
pubmed: 31028669
J Med Chem. 2017 Mar 9;60(5):1648-1661
pubmed: 28124907
J Med Chem. 2014 Mar 13;57(5):1812-25
pubmed: 23547794
Sci Rep. 2020 Jun 9;10(1):9294
pubmed: 32518317
Antimicrob Agents Chemother. 2015 Dec 14;60(3):1264-73
pubmed: 26666922
AIDS. 1996 May;10(5):485-92
pubmed: 8724039
J Infect Dis. 2004 Jan 15;189(2):265-72
pubmed: 14722892
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282
Antimicrob Agents Chemother. 2009 Mar;53(3):926-34
pubmed: 19075052
J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):449-55
pubmed: 23807155
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
Nat Commun. 2020 Aug 13;11(1):4059
pubmed: 32792628
J Med Chem. 2014 Mar 13;57(5):1893-901
pubmed: 24144213
Cell Host Microbe. 2020 May 13;27(5):841-848.e3
pubmed: 32289263
J Biomol Struct Dyn. 2022 Oct;40(16):7367-7380
pubmed: 33734021
Clin Infect Dis. 2020 Dec 31;71(11):2787-2795
pubmed: 31915807
Med Mal Infect. 2020 Jun;50(4):384
pubmed: 32240719
JAMA. 2004 Jul 14;292(2):180-9
pubmed: 15249567
HIV Clin Trials. 2004 Nov-Dec;5(6):371-82
pubmed: 15682350
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62
pubmed: 24043791
Ann Pharmacother. 2002 Jan;36(1):102-18
pubmed: 11816239
Life Sci. 2020 Jul 15;253:117592
pubmed: 32222463
AIDS. 2000 Oct 20;14(15):2293-7
pubmed: 11089617
Antimicrob Agents Chemother. 2005 Dec;49(12):4980-8
pubmed: 16304161
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6
pubmed: 9878993
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Antiviral Res. 2013 Aug;99(2):100-7
pubmed: 23648708
Antiviral Res. 2018 Dec;160:109-117
pubmed: 30316915
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Cell Host Microbe. 2016 Jun 8;19(6):891-900
pubmed: 27198478
Nucleosides Nucleotides Nucleic Acids. 2012 Apr;31(4):277-85
pubmed: 22444190
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5193-5194
pubmed: 32495848
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2415-2427
pubmed: 31230974
Virology. 1998 Oct 25;250(2):255-62
pubmed: 9792836
AIDS. 2006 Aug 22;20(13):1721-6
pubmed: 16931936
Clin Pharmacol Ther. 2008 Jun;83(6):867-72
pubmed: 17898705
J Med Chem. 2005 Mar 24;48(6):1813-22
pubmed: 15771427
Antiviral Res. 2011 Jul;91(1):11-9
pubmed: 21575658
Antimicrob Agents Chemother. 2011 Sep;55(9):4196-203
pubmed: 21746939
J Antimicrob Chemother. 2012 Feb;67(2):465-8
pubmed: 22121190
Antimicrob Agents Chemother. 2014;58(2):647-53
pubmed: 23939899
Drugs. 1996 Oct;52(4):541-6; discussion 547-8
pubmed: 8891466
J Biol Chem. 2020 May 15;295(20):6785-6797
pubmed: 32284326
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
Drugs. 2000 Mar;59(3):581-620
pubmed: 10776836